Advanced Search
CHENG Xingyu, XU Jia, LIU Lei, WANG An'an, LUO Yonghui. Advances in Endocrine Combination Therapy on Hormone-receptor-positive Advanced Breast Cancer[J]. Cancer Research on Prevention and Treatment, 2017, 44(10): 706-709. DOI: 10.3971/j.issn.1000-8578.2017.16.1631
Citation: CHENG Xingyu, XU Jia, LIU Lei, WANG An'an, LUO Yonghui. Advances in Endocrine Combination Therapy on Hormone-receptor-positive Advanced Breast Cancer[J]. Cancer Research on Prevention and Treatment, 2017, 44(10): 706-709. DOI: 10.3971/j.issn.1000-8578.2017.16.1631

Advances in Endocrine Combination Therapy on Hormone-receptor-positive Advanced Breast Cancer

  • Hormone-receptor-positive advanced breast cancer is an incurable heterogeneous malignant tumor, seriously affecting the health and life of women. The clinical benefit of endocrine follow-up treatment is unsatisfactory due to the changes of tumor biological behavior and its drugs resistance. In recent years, many agents targeting the intracellular signaling pathways associated with endocrine resistance are in development and significantly improve the patients' progression-free survival (PFS) and quality of life, providing more evidence for follow-up endocrine therapy on advanced breast cancer. This article reviews the latest advances in endocrine combination therapy on advanced breast cancer.
  • loading

Catalog

    Turn off MathJax
    Article Contents

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return